KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Finished Goods (2016 - 2025)

Resmed (RMD) has disclosed Finished Goods for 16 consecutive years, with $546.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Finished Goods rose 6.14% year-over-year to $546.3 million, compared with a TTM value of $546.3 million through Dec 2025, up 6.14%, and an annual FY2025 reading of $557.9 million, up 20.24% over the prior year.
  • Finished Goods was $546.3 million for Q4 2025 at Resmed, down from $580.5 million in the prior quarter.
  • Across five years, Finished Goods topped out at $580.5 million in Q3 2025 and bottomed at $265.6 million in Q4 2021.
  • Average Finished Goods over 5 years is $453.7 million, with a median of $489.3 million recorded in 2024.
  • The sharpest move saw Finished Goods skyrocketed 96.76% in 2022, then fell 21.89% in 2024.
  • Year by year, Finished Goods stood at $265.6 million in 2021, then soared by 96.76% to $522.5 million in 2022, then dropped by 11.38% to $463.0 million in 2023, then rose by 11.16% to $514.7 million in 2024, then rose by 6.14% to $546.3 million in 2025.
  • Business Quant data shows Finished Goods for RMD at $546.3 million in Q4 2025, $580.5 million in Q3 2025, and $557.9 million in Q2 2025.